These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 24152197)

  • 1. Low-dose heparin for elective percutaneous coronary intervention.
    Lee MS; Oyama J; Iqbal Z; Tarantini G
    J Interv Cardiol; 2014 Feb; 27(1):58-62. PubMed ID: 24152197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percutaneous Coronary Intervention With an Initial Bolus of Low-Dose Heparin in Biomarker-Negative Patients.
    Lee MS; Rha SW; Shlofmitz R
    Cardiovasc Revasc Med; 2021 Feb; 23():38-41. PubMed ID: 32703583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial.
    Montalescot G; Gallo R; White HD; Cohen M; Steg PG; Aylward PE; Bode C; Chiariello M; King SB; Harrington RA; Desmet WJ; Macaya C; Steinhubl SR;
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1083-91. PubMed ID: 19926048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of low-dose unfractionated heparin during percutaneous coronary revascularisation and the relationship between activated clotting time and haemorrhagic or ischaemic complications: our results.
    Capuano C; Sesana M; Leonzi O; Cuccia C
    J Cardiovasc Med (Hagerstown); 2006 Dec; 7(12):866-71. PubMed ID: 17122672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CIAO (Coronary Interventions Antiplatelet-based Only) Study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention.
    Stabile E; Nammas W; Salemme L; Sorropago G; Cioppa A; Tesorio T; Ambrosini V; Campopiano E; Popusoi G; Biondi Zoccai G; Rubino P
    J Am Coll Cardiol; 2008 Oct; 52(16):1293-8. PubMed ID: 18929239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention.
    Schulz S; Mehilli J; Neumann FJ; Schuster T; Massberg S; Valina C; Seyfarth M; Pache J; Laugwitz KL; Büttner HJ; Ndrepepa G; Schömig A; Kastrati A;
    Eur Heart J; 2010 Oct; 31(20):2482-91. PubMed ID: 20805113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of coronary stenting with eptifibatide and ultra-low-dose heparin.
    Le May M; Kurdi M; Labinaz M; Glover C; So D; Ryan S; Davies R
    Am J Cardiol; 2005 Mar; 95(5):630-2. PubMed ID: 15721106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of the antithrombotlic effect and safety between intravenous nadroparin and unfractionated heparin in patients undergoing percutaneous coronary intervention].
    Zhu JH; Qiu YG; Chen JZ; Zhang FR; Fu GS; Shen FR; Huang WJ; Wang JA; Zhao LL; Tao QM; Zheng LR
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Apr; 33(4):335-9. PubMed ID: 15932664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction.
    Rozenman Y; Mehran R; Witzenbichler B; Dangas G; Desaga M; Kochman J; Nilsen DW; Finkelstein A; Mosseri M; Stone GW
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):E9-14. PubMed ID: 22511592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention.
    Denardo SJ; Davis KE; Tcheng JE
    Am J Cardiol; 2007 Nov; 100(9):1376-82. PubMed ID: 17950793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
    Montalescot G; White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Chiariello M; King SB; Harrington RA; Desmet WJ; Macaya C; Steinhubl SR;
    N Engl J Med; 2006 Sep; 355(10):1006-17. PubMed ID: 16957147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
    Bertrand OF; Rodés-Cabau J; Rinfret S; Larose E; Bagur R; Proulx G; Gleeton O; Costerousse O; De Larochellière R; Roy L
    Am J Cardiol; 2009 Nov; 104(9):1235-40. PubMed ID: 19840568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG Investigators
    N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial.
    Rao SV; Melloni C; Myles-Dimauro S; Broderick S; Kosinski AS; Kleiman NS; Dzavík V; Tanguay JF; Chandna H; Gammon R; Rivera E; Alexander JH; Fier I; Roach J; Becker RC;
    Circulation; 2010 Apr; 121(15):1713-21. PubMed ID: 20368520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
    White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Steinhubl S; Montalescot G
    Am Heart J; 2009 Jan; 157(1):125-31. PubMed ID: 19081408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial.
    Sambola A; Montoro JB; Del Blanco BG; Llavero N; Barrabés JA; Alfonso F; Bueno H; Cequier A; Serra A; Zueco J; Sabaté M; Rodríguez-Leor O; García-Dorado D
    Am Heart J; 2013 Oct; 166(4):669-75. PubMed ID: 24093846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Feit A; Battala VR; Cavusoglu E
    J Invasive Cardiol; 2008 Jul; 20(7):323-7. PubMed ID: 18599887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
    Lamberts M; Gislason GH; Olesen JB; Kristensen SL; Schjerning Olsen AM; Mikkelsen A; Christensen CB; Lip GY; Køber L; Torp-Pedersen C; Hansen ML
    J Am Coll Cardiol; 2013 Sep; 62(11):981-9. PubMed ID: 23747760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The REDUCED (a RandomisED stUdy Comparing standard systemic anticoagulation thErapy to low Dose intracoronary anticoagulation therapy for elective percutaneous coronary intervention) trial. A novel pharmacologic regime for elective percutaneous coronary intervention.
    Ari H; Kivaç E; Ari S; Emlek N; Cetinkaya S; Celiloğlu N; Sarigul OY; Aydin C; Akkaya M; Koca V; Bozat T; Gurdogan M
    Acta Cardiol; 2014 Dec; 69(6):619-27. PubMed ID: 25643432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.